Meeting
2019 Genitourinary Cancers Symposium
Effect of IL-6 and related mediators on resistance to abiraterone acetate (abi) and enzalutamide (enza) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Jacob J. Adashek
City of Hope Comprehensive Cancer Center, Duarte, CA
Jacob J. Adashek , Haejung Won , Dayson Moreira , Priyanka Duttagupta , Przemyslaw Twardowski , Jeremy Jones , Marcin Kortylewski , Sumanta K. Pal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 296)
DOI
10.1200/JCO.2019.37.7_suppl.296
Abstract #
296
Poster Bd #
D4
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Differences in immune tumor microenvironment between primary and metastatic castration-resistant prostate cancer.
First Author: Yuanquan Yang
Poster
2022 ASCO Genitourinary Cancers Symposium
Association of circulating tumor cell RB1 loss RNA signature with outcomes and immune phenotypes in men with mCRPC.
First Author: Jiaren Zhang
Poster
2022 ASCO Genitourinary Cancers Symposium
ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
First Author: Louise Emmett
Poster
2022 ASCO Genitourinary Cancers Symposium
Immune characterization of urothelial bladder carcinoma integrating transurethral resection of bladder tumor (TURBT) samples and serum: A feasibility study.
First Author: Carmen Alvarez-Dominguez